- US11845729utility2023Processes and Intermediates in the Preparation of C5ar Antagonists0 cites
- US11834452utility2023CXCR7 Antagonists0 cites
- US11820759utility2023Modulators of Chemokine Receptors0 cites
- US11807609utility2023Deuterated Compounds as Immunomodulators0 cites
- US11793771utility2023Immunomodulator Compounds0 cites
- US11779576utility2023Method of Treating C3 Glomerulopathy0 cites
- US11773091utility20236-5 Fused Rings as C5a Inhibitors0 cites
- US11759454utility2023Diazole Lactams0 cites
- US11759458utility2023Indane-amines as PD-L1 Antagonists0 cites
- US11744822utility2023Reducing Tumor Burden by Administering CCR1 Antagonists in Combination with PD-1 Inhibitors or PD-L1 Inhibitors0 cites
- US11713307utility2023Heteroaryl-biphenyl Amides for the Treatment of PD-L1 Diseases0 cites
- US11708326utility2023Immunomodulator Compounds0 cites
- US11691985utility2023Macrocyclic Immunomodulators0 cites
- US11684606utility2023Methods of Treating Generalized Pustular Psoriasis with an Antagonist of CCR6 or CXCR20 cites
- US11608336utility2023Prodrugs of Fused-bicyclic C5ar Antagonists0 cites
- US11603356utility2023Amorphous Form of a Complement Component C5a Receptor0 cites
← PreviousPage 2 of 2